# A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus

Study · id `cardio:ct-nct01952145` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01952145](<https://clinicaltrials.gov/study/NCT01952145>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01952145

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 557 participants.

## Technical summary

Registry record NCT01952145. Randomized; no masking; primary purpose treatment. Start 2013-09-20 (actual); primary completion 2014-11-04 (actual). Results posted on 2017-01-20.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 557 participants (enrolled count; ClinicalTrials.gov record NCT01952145, source copy `cardio:ctgov-nct01952145-2019-01-03`, retrieved 2026-10-26)
- Started: 2013-09-20 (actual) (ClinicalTrials.gov record NCT01952145, source copy `cardio:ctgov-nct01952145-2019-01-03`, retrieved 2026-10-26)
- Primary completion: 2014-11-04 (actual) (ClinicalTrials.gov record NCT01952145, source copy `cardio:ctgov-nct01952145-2019-01-03`, retrieved 2026-10-26)
- Completion: 2014-11-04 (actual) (ClinicalTrials.gov record NCT01952145, source copy `cardio:ctgov-nct01952145-2019-01-03`, retrieved 2026-10-26)
- Results first posted: 2017-01-20 (ClinicalTrials.gov record NCT01952145, source copy `cardio:ctgov-nct01952145-2019-01-03`, retrieved 2026-10-26)
- Countries: United States; Argentina; Australia; Greece; Hungary; Mexico; Russia; Slovakia; South Africa; Spain (ClinicalTrials.gov record NCT01952145, source copy `cardio:ctgov-nct01952145-2019-01-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01952145-2019-01-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide Versus Insulin Glargine in Subjects With Type 2 Diabetes Mellitus
- Acronym: DUAL™ V
- Condition: Diabetes
- Condition: Diabetes Mellitus, Type 2
- Intervention (Drug): insulin degludec/liraglutide
- Intervention (Drug): insulin glargine
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

### Main results

- Registry lists this paper as a reference of type result; PubMed types it as a trial report that names this trial and no other, dated on or after the trial start, and its title marks no secondary, follow-up or other further analysis: Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial (`cardio:pubmed-26934259`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Evaluation of the long-term cost-effectiveness of IDegLira versus liraglutide added to basal insulin for patients with type 2 diabetes failing to achieve glycemic control on basal insulin in the USA (`cardio:pubmed-28294641`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA (`cardio:pubmed-28281218`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial (`cardio:pubmed-28643425`)
- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES (`cardio:pubmed-30383495`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: e197812521c6a662871fb682ae88001b0748bb4c95cf70ff5c1cf9a6ce75abb9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
